Quick Answer
Ovid Therapeutics Inc. reported Cash And Cash Equivalents At Carrying Value of $13.15 million for the year ending 2025.
- Ovid Therapeutics Inc. showed a decrease of -50.0% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Ovid Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), Ovid Therapeutics Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 171.4%.
- Historical annual values: Fiscal year 2025: $13.15 million | Fiscal year 2024: $26.30 million | Fiscal year 2023: $27.04 million | Fiscal year 2022: $44.87 million | Fiscal year 2021: $187.80 million | Fiscal year 2020: $72.03 million | Fiscal year 2019: $41.90 million | Fiscal year 2018: $36.49 million | Fiscal year 2017: $87.13 million | Fiscal year 2016: $51.94 million | Fiscal year 2015: $69.94 million | Fiscal year 2014: $4.85 million.
- Data sourced from SEC EDGAR public filings as of June 24, 2026.
Last verified: